A Phase 1 interventional study of RJK002 Intrathecal injection in Amyotrophic Lateral Sclerosis Als, sponsored by RJK Biopharma Ltd. Active, not recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-20.
Sponsored by RJK Biopharma Ltd · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 55 studies in Amyotrophic Lateral Sclerosis with a site in China — 24 open to participants now, 29 under way, 1 of them phase 3. Amyotrophic Lateral Sclerosis · China.
Among the 55 studies in Amyotrophic Lateral Sclerosis with a site in China, this one is the 31st largest by planned enrollment of the 39 interventional ones that give a count, is one of 9 that started in 2024, is one of 14 in phase 1, reaches primary completion later than 10 of the 28 other live ones, and was the 34th registered.
981 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 280 are open to participants now.
Browse Amyotrophic Lateral Sclerosis studies →24 of the 55 studies in Amyotrophic Lateral Sclerosis with a site in China are open now. Recruiting first, the newest first:
Talengen Institute of Life Sciences, Shenzhen, P.R. China. · Sites in China
Ages 18+
Shanghai Zhimeng Biopharma, Inc. · Sites in China
Ages 18–65
XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd. · Sites in China
Ages 18–75
First People's Hospital of Hangzhou · Sites in China
Ages 18–80
Shanghai StairMed Technology Co., Ltd. · Sites in China
Ages 18–80
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 194 Amyotrophic Lateral Sclerosis studies recruiting now, 119 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 56 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
55 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 15 · Phase 3 2 · Phase 4 3
First in 2006; this study’s year is marked. 9 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 9 is below the median of 38 across 664 interventional studies indexed under Amyotrophic Lateral Sclerosis.
Median enrollment 24 across the 39 interventional studies, 226 across the 16 observational. Of the 10 that completed or were terminated, 1 (10%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 55 have an industry lead sponsor. The 10 most frequent:
RJK Biopharma Ltd is the lead sponsor of 2 studies on the registry; none are open to participants now.
RJK Biopharma Ltd has 2 studies filed under Amyotrophic Lateral Sclerosis — fewer than ten, so there is no comparison to draw.
12 of the studies in Amyotrophic Lateral Sclerosis with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07082192Phase 3Shanghai Zhimeng Biopharma, Inc.A Study to Evaluate the Efficacy and Safety of Different Doses of CB03-154 in Adult Patients With Amyotrophic Lateral Sclerosis (ALS) | 2027-09-30 |
| NCT06493279RJK Biopharma LtdEvaluate the Safety and Efficacy of Intrathecal Injection of RJK002 in Patients With Amyotrophic Lateral Sclerosis | 2026-11-30 |
| NCT06671236Novabio TherapeuticsClinical Study of Regulatory T Cells (Tregs) in the Treatment of Neurodegenerative Diseases | 2026-12 |
| NCT06765499First People's Hospital of HangzhouThe Study Evaluating the Improvement of Nutritional Status and Frailty With Silkworm Pupa Powder Among Patients With Motor Neuron Disease | 2026-12-30 |
| NCT06726577Talengen Institute of Life Sciences, Shenzhen, P.R. China.TP04HN106 in the Treatment of Patients With Amyotrophic Lateral Sclerosis | 2027-01 |
Add all 12 to your calendar (.ics) → With an account.
Among the 55 studies in Amyotrophic Lateral Sclerosis with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of the study aims to evaluate the safety and tolerability of a single intrathecal injection of RJK002 in subjects with amyotrophic lateral sclerosis (ALS), and to determine the recommended Phase II dose (RP2D).
Main Inclusion Criteria:
Main Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Eligible subjects will receive a single intrathecal administration of investigational product. 9 subjects will be involved in 3 doses cohort from low to high: 6E13 vg/person, 1.2E14 vg/person, and 2.4E14 vg/person, 3 subjects for each cohort.
Drug: RJK002 Intrathecal injection
Eligible subjects will receive a single intrathecal administration of investigational product with dose 3E13vg (3ml), 6E13vg(6ml), and 1.2E14 vg(12ml) per person sequentially.
incidence of adverse events (AEs)/serious adverse events (SAEs)
Time frame: Each visit within 5 years after administration
Dose limiting toxicities (DLT)
Measured as any drug-related serious adverse event that meet DLT standard. If a dose has less than 33% DLTs it will be considered tolerable.
Time frame: 28 days after administration
Change in the ALS Functional Rating Scale-revised (ALSFRSr) Score
The ALSFRSr, a questionnaire-based scale assessing daily living function ranging from 48 (best score) to 0 (worst), was administered to the patient, or to a proxy if the patient could not communicate effectively. Decline was defined as ALSFRSr at baseline minus ALSFRSr at month 9. A positive value indicates worsening.
Time frame: 28 days, 56 days, 84 days, 6 months, 12months, 18 months after administration
change of concentration of neurofilament light chain (NFL) in blood and CSF
Time frame: 84 days, 6 months, 12months, 18 months after administration
Plan to share: Yes — Part of the data are planed to share on Oct 2025, Oct 2026, and Sep 2032.
Supporting information: Clinical study report
No publications or documents are linked to this record.
Started Sep 2024 (actual). Primary completion is estimated for Nov 2026, 26 months after the start.
Of 40 industry-sponsored phase 1 interventional studies under Amyotrophic Lateral Sclerosis, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 38. This study's planned 26 months is above that.
Counting every sponsor, half of 70 studies reached it within 21 months; a quarter within 13 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Amyotrophic Lateral Sclerosis →
RJK Biopharma Ltd